Relation between TLR4/NF-κB signaling pathway activation by 27-hydroxycholesterol and 4-hydroxynonenal, and atherosclerotic plaque instability

Aging Cell

Volumn 14, Issue 4, 2015, Pages 569-581

  Gargiulo, Simona ^a   Gamba, Paola ^a   Testa, Gabriella ^a   Rossin, Daniela ^a   Biasi, Fiorella ^a   Poli, Giuseppe ^a   Leonarduzzi, Gabriella ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

27 Hydroxycholesterol; 4 Hydroxynonenal; Atherosclerosis; Cytokines; MMP 9; TLR4

Indexed keywords

26 HYDROXYCHOLESTEROL; 4 HYDROXYNONENAL; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; INTERLEUKIN 8; OXIDIZED LOW DENSITY LIPOPROTEIN; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR; 27-HYDROXYCHOLESTEROL; 4-HYDROXY-2-NONENAL; ALDEHYDE; CHOLESTEROL DERIVATIVE; SMALL INTERFERING RNA; TLR4 PROTEIN, HUMAN;

ARTICLE; ATHEROSCLEROTIC PLAQUE; CONTROLLED STUDY; CYTOKINE RELEASE; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMONOCYTIC CELL; PROTEIN DEGRADATION; TLR SIGNALING; U-937 CELL LINE; UPREGULATION; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CELL LINE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MONOCYTE; PATHOLOGY; SIGNAL TRANSDUCTION;

ALDEHYDES; CELL LINE; GENE EXPRESSION REGULATION; HUMANS; HYDROXYCHOLESTEROLS; INTERLEUKIN-1BETA; INTERLEUKIN-8; MATRIX METALLOPROTEINASE 9; MODELS, BIOLOGICAL; MONOCYTES; NF-KAPPA B; PLAQUE, ATHEROSCLEROTIC; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84924370418     PISSN: 14749718     EISSN: 14749726     Source Type: Journal    
DOI: 10.1111/acel.12322     Document Type: Article

References (55)

1. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, Lamotte M, Lebret D, Ollivier V, de Prost D (2003) Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler. Thromb. Vasc. Biol. 23, e61-e64.
2. Bijani FM, Vallejo JG, Rezaei N (2012) Toll-like receptor signaling pathways in cardiovascular diseases: challenges and opportunities. Int. Rev. Immunol. 31, 379-395.
3. Björkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW (2004) Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat. Med. 10, 416-421.
4. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van der Wall EE, Reitsma PH, Kastelein JJ, Jukema JW, REgression GRowth Evaluation Statin Study Group (2003) Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 107, 2416-2421.
5. Chávez-Sánchez L, Madrid-Miller A, Chávez-Rueda K, Legorreta-Haquet MV, Tesoro-Cruz E, Blanco-Favela F (2010) Activation of TLR2 and TLR4 by minimally modified low-density lipoprotein in human macrophages and monocytes triggers the inflammatory response. Hum. Immunol. 71, 737-744.
6. Chávez-Sánchez L, Garza-Reyes MG, Espinosa-Luna JE, Chávez-Rueda K, Legorreta- Haquet MV, Blanco-Favela F (2014) The role of TLR2, TLR4 and CD36 in macrophage activation and foam cell formation in response to oxLDL in humans. Hum. Immunol. 75, 322-329.
7. Choi SH, Harkewicz R, Lee JH, Boullier A, Almazan F, Li AC, Witztum JL, Bae YS, Miller YI (2009) Lipoprotein accumulation in macrophages via toll-like receptor- 4-dependent fluid phase uptake. Circ. Res. 104, 1355-1363.
8. Cole JE, Kassiteridi C, Monaco C (2013) Toll-like receptors in atherosclerosis: a ‘Pandora’s box’ of advances and controversies. Trends Pharmacol. Sci. 34, 629-636.
9. Curtiss LK, Tobias PS (2009) Emerging role of Toll-like receptors in atherosclerosis. J. Lipid Res. 50, S340-S345.
10. den Dekker WK, Cheng C, Pasterkamp G, Duckers HJ (2010) Toll like receptor 4 in atherosclerosis and plaque destabilization. Atherosclerosis 209, 314-320.
11. Doyle SE, O’Connell RM, Miranda GA, Vaidya SA, Chow EK, Liu PT, Suzuki S, Suzuki N, Modlin RL, Yeh WC, Lane TF, Cheng G (2004) Toll-like receptors induce a phagocytic gene program through p38. J. Exp. Med. 199, 81-90.
12. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ (2002) Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 105, 1158-1161.
13. Erridge C, Webb DJ, Spickett CM (2007) 25-hydroxycholesterol, 7beta-hydroxycholesterol and 7-ketocholesterol upregulate interleukin-8 expression independently of Toll-like receptor 1, 2, 4 or 6 signalling in human macrophages. Free Radic. Res. 41, 260-266.
14. Esterbauer H, Schaur RJ, Zollner H (1991) Chemistry and biochemistry of 4- hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11, 81-128.
15. Fratta Pasini A, Anselmi M, Garbin U, Franchi E, Stranieri C, Nava MC, Boccioletti V, Vassanelli C, Cominacini L (2007) Enhanced levels of oxidized low-density lipoprotein prime monocytes to cytokine overproduction via upregulation of CD14 and toll-like receptor 4 in unstable angina. Arterioscler. Thromb. Vasc. Biol. 27, 1991-1997.
16. Gargiulo S, Sottero B, Gamba P, Chiarpotto E, Poli G, Leonarduzzi G (2011) Plaque oxysterols induce unbalanced up-regulation of matrix metalloproteinase-9 in macrophagic cells through redox-sensitive signaling pathways: implications regarding the vulnerability of atherosclerotic lesions. Free Radic. Biol. Med. 51, 844-855.
17. Gebbia JA, Coleman JL, Benach JL (2004) Selective induction of matrix metalloproteinases by Borrelia burgdorferi via toll-like receptor 2 in monocytes. J. Infect. Dis. 189, 113-119.
18. Geng HL, Lu HQ, Zhang LZ, Zhang H, Zhou L, Wang H, Zhong RQ (2006) Increased expression of Toll like receptor 4 on peripheral-blood mononuclear cells in patients with coronary arteriosclerosis disease. Clin. Exp. Immunol. 143, 269-273.
19. Hansson GK (2001) Immune mechanisms in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 21, 1876-1890.
20. Hernesniemi JA, Raitakari OT, Kähönen M, Juonala M, Hutri-Kähönen N, Marniemi J, Viikari J, Lehtimäki T (2008) Toll-like receptor 4 gene (Asp299Gly) polymorphism associates with carotid artery elasticity. The cardiovascular risk in young Finns study. Atherosclerosis 198, 152-159.
21. Higashimori M, Tatro JB, Moore KJ, Mendelsohn ME, Galper JB, Beasley D (2011) Role of toll-like receptor 4 in intimal foam cell accumulation in apolipoprotein Edeficient mice. Arterioscler. Thromb. Vasc. Biol. 31, 50-57.
22. Hollestelle SC, De Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, Van Middelaar BJ, Pasterkamp G, Quax PH, De Kleijn DP (2004) Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 109, 393-398.
23. Ikeda T, Funaba M (2003) Altered function of murine mast cells in response to lipopolysaccharide and peptidoglycan. Immunol. Lett. 88, 21-26.
24. Ishikawa Y, Satoh M, Itoh T, Minami Y, Takahashi Y, Akamura M (2008) Local expression of Toll-like receptor 4 at the site of ruptured plaques in patients with acute myocardial infarction. Clin. Sci. (Lond.) 115, 133-140.
25. Jeong E, Lee JY (2011) Intrinsic and extrinsic regulation of innate immune receptors. Yonsei Med. J. 52, 379-392.
26. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, Willeit J, Schwartz DA (2002) Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185-192.
27. Kim YS, Park ZY, Kim SY, Jeong E, Lee JY (2009) Alteration of Toll-like receptor 4 activation by 4-hydroxy-2-nonenal mediated by the suppression of receptor homodimerization. Chem. Biol. Interact. 182, 59-66.
28. Leonarduzzi G, Chiarpotto E, Biasi F, Poli G (2005) 4-Hydroxynonenal and cholesterol oxidation products in atherosclerosis. Mol. Nutr. Food Res. 49, 1044-1049.
29. Leonarduzzi G, Poli G, Sottero B, Biasi F (2007) Activation of the mitochondrial pathway of apoptosis by oxysterols. Front Biosci. 12, 791-799.
30. Li H, Xu H, Sun B (2012) Lipopolysaccharide regulates MMP-9 expression through TLR4/NF-jB signaling in human arterial smooth muscle cells. Mol. Med. Rep. 6, 774-778.
31. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using realtime quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402-408.
32. Lu Z, Li Y, Jin J, Zhang X, Lopes-Virella MF, Huang Y (2012) Toll-like receptor 4 activation in microvascular endothelial cells triggers a robust inflammatory response and cross talk with mononuclear cells via interleukin-6. Arterioscler. Thromb. Vasc. Biol. 32, 1696-1706.
33. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, Koglin J (2005) Expansion of circulating Toll-like receptor 4-positive monocytes in patients with acute coronary syndrome. Circulation 111, 2654-2661.
34. Michelsen KS, Wong MH, Shah PK, Zhang W, Yano J, Doherty TM, Akira S, Rajavashisth TB, Arditi M (2004) Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E. Proc. Natl. Acad. Sci. USA 101, 10679-10684.
35. Miller YI, Viriyakosol S, Worrall DS, Boullier A, Butler S, Witztum JL (2005) Toll-like receptor 4-dependent and -independent cytokine secretion induced by minimally oxidized low-density lipoprotein in macrophages. Arterioscler. Thromb. Vasc. Biol. 25, 1213-1219.
36. Miller YI, Choi SH, Fang L, Harkewicz R (2009) Toll-like receptor-4 and lipoprotein accumulation in macrophages. Trends Cardiovasc. Med. 19, 227-232.
37. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M (1999) Interleukin- 8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 99, 420-426.
38. Netea MG, Hijmans A, van Wissen S, Smilde TJ, Trip MD, Kullberg BJ, de Boo T, Van der Meer JW, Kastelein JJ, Stalenhoef AF (2004) Toll-like receptor-4 Asp299Gly polymorphism does not influence progression of atherosclerosis in patients with familial hypercholesterolaemia. Eur. J. Clin. Invest. 34, 94-99.
39. Paolillo R, Iovene MR, Romano Carratelli C, Rizzo A (2012) Induction of VEGF and MMP-9 expression by toll-like receptor 2/4 in human endothelial cells infected with Chlamydia pneumoniae. Int. J. Immunopathol. Pharmacol. 25, 377-386.
40. Pasterkamp G, Van Keulen JK, De Kleijn DP (2004) Role of Toll-like receptor 4 in the initiation and progression of atherosclerotic disease. Eur. J. Clin. Invest. 34, 328-334.
41. Poli G, Schaur RJ, Siems WG, Leonarduzzi G (2008) 4-Hydroxynonenal: a membrane lipid oxidation product of medicinal interest. Med. Res. Rev. 28, 569-631.
42. Poli G, Sottero B, Gargiulo S, Leonarduzzi G (2009) Cholesterol oxidation products in the vascular remodeling due to atherosclerosis. Mol. Aspects Med. 30, 180-189.
43. Schoneveld AH, Hoefer I, Sluijter JP, Laman JD, de Kleijn DP, Pasterkamp G (2008) Atherosclerotic lesion development and Toll like receptor 2 and 4 responsiveness. Atherosclerosis 197, 95-104.
44. Seneviratne AN, Sivagurunathan B, Monaco C (2012) Toll-like receptors and macrophage activation in atherosclerosis. Clin. Chim. Acta 413, 3-14.
45. Sottero B, Gamba P, Gargiulo S, Leonarduzzi G, Poli G (2009) Cholesterol oxidation products and disease: an emerging topic of interest in medicinal chemistry. Curr. Med. Chem. 16, 685-705.
46. Steinberg D (2002) Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat. Med. 8, 1211-1217.
47. Tang SC, Lathia JD, Selvaraj PK, Jo DG, Mughal MR, Cheng A, Siler DA, Markesbery WR, Arumugam TV, Mattson MP (2008) Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid beta-peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213, 114-121.
48. Vink A, Schoneveld AH, van der Meer JJ, van Middelaar BJ, Sluijter JP, Smeets MB, Quax PH, Lim SK, Borst C, Pasterkamp G, de Kleijn DP (2002) In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 106, 1985-1990.
49. Vink A, de Kleijn DP, Pasterkamp G (2004) Functional role for toll-like receptors in atherosclerosis and arterial remodeling. Curr. Opin. Lipidol. 15, 515-521.
50. Walton KA, Hsieh X, Gharavi N, Wang S, Wang G, Yeh M, Cole AL, Berliner JA (2003a) Receptors involved in the oxidized 1-palmitoyl-2-arachidonoyl-snglycero- 3-phosphorylcholine-mediated synthesis of interleukin-8. A role for Toll-like receptor 4 and a glycosylphosphatidylinositol-anchored protein. J. Biol. Chem. 278, 29661-29666.
51. Walton KA, Cole AL, Yeh M, Subbanagounder G, Krutzik SR, Modlin RL, Lucas RM, Nakai J, Smart EJ, Vora DK, Berliner JA (2003b) Specific phospholipid oxidation products inhibit ligand activation of toll-like receptors 4 and 2. Arterioscler. Thromb. Vasc. Biol. 23, 1197-1203.
52. Xu XH, Shah PK, Faure E, Equils O, Thomas L, Fishbein MC, Luthringer D, Xu XP, Rajavashisth TB, Yano J, Kaul S, Arditi M (2001) Toll-like receptor-4 is expressed by macrophages in murine and human lipid-rich atherosclerotic plaques and upregulated by oxidized LDL. Circulation 104, 3103-3108.
53. Yang K, He YS, Wang XQ, Lu L, Chen QJ, Liu J, Sun Z, Shen WF (2011) MiR- 146a inhibits oxidized low-density lipoprotein-induced lipid accumulation and inflammatory response via targeting toll-like receptor 4. FEBS Lett. 585, 854-860.
54. Yang K, Zhang XJ, Cao LJ, Liu XH, Liu ZH, Wang XQ, Chen QJ, Lu L, Shen WF, Liu Y (2014) Toll-like receptor 4 mediates inflammatory cytokine secretion in smooth muscle cells induced by oxidized low-density lipoprotein. PLoS ONE 9, e95935.
55. Zhong Y, Yu W, Feng J, Fan Z, Li J (2014) Curcumin suppresses tumor necrosis factor-a-induced matrix metalloproteinase-2 expression and activity in rat vascular smooth muscle cells via the NF-jB pathway. Exp. Ther. Med. 7, 1653-1658.